Intra-Cellular Therapies Net Tangible Assets

The latest net tangible assets for ITCI is $1.1B as of December 2024. That compares with $590M in the prior-year period — up 94.2% year over year. Investors often review this figure alongside Intra-Cellular Therapies's historical trend and sector peers before judging valuation or financial health.

Over the past year, ITCI's net tangible assets moved from $590M to $1.1B — a 94.2% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Intra-Cellular Therapies's operating scale or balance-sheet position.

A net tangible assets figure of $1.1B for ITCI is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting ITCI's net tangible assets ($1.1B), review year-over-year change from $590M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Intra-Cellular Therapies's net tangible assets against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.